Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics (PERCF)
OTHER OTC:PERCF
PERCF Stock Chart & Stats
$0.01
<$0.01(11.11%)
At close: 4:00 PM EST
$0.01
<$0.01(11.11%)
Day’s Range― - ―
52-Week Range$0.01 - $0.02
Previous CloseN/A
Volume44.70K
Average Volume (3M)3.33K
Market Cap
$6.16M
Enterprise Value-$1.44M
Total Cash (Recent Filing)$10.17M
Total Debt (Recent Filing)$25.86K
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Feb 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,087,437,600
10 Day Avg. Volume0
30 Day Avg. Volume3,333
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.65
Enterprise Value/Market Cap-0.23
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit21.22
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Percheron Therapeutics News
PERCF FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest stock price was $0.01 and its highest was $0.02 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is $6.16M.
When is Percheron Therapeutics’s upcoming earnings report date?
Percheron Therapeutics’s upcoming earnings report date is Feb 25, 2026 which is in 15 days.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Aug 28, 2025. The company reported -$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.004.
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Overvalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,087,437,600 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in PERCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
PERCF Sentiment 81%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth AU$25.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-151.35%
Trailing 12-Months
Asset Growth
-16.01%
Trailing 12-Months
Company Description
Percheron Therapeutics
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---